AMRX vs GE · P/E 44, rev $2.79B vs P/E 44, rev $45.85B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus GE Aerospace (GE) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
GE Aerospace (GE) is a aerospace & defense company listed on NYSE. It is led by Larry Culp.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported GE revenue for 2025-12-31 was $45.85B. Net income was $8.70B. Revenue was up 324.1% from 2024-12-31 to 2025-12-31. GE currently screens at market cap $373.04B and trailing P/E 44.4.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. GE currently screens at market cap $373.04B and trailing P/E 44.4.
Not investment advice. Open the AMRX and GE stock pages for the full models.
Not investment advice.